Resources

Thrombosis News

• The future treatment of deep vein thrombosis looks set to revolutionise Results of a significant Phase III EINSTEIN-DVT study, presented at the European Society of Cardiology (ESC), confirmed that, for the first time since the introduction of warfarin 55 years ago, we have taken a step towards being able to potentially offer an oral single-drug approach as an alternative to traditional standard treatment [a combination of low molecular weight heparin (LMWH) and warfarin] to patients with deep vein thrombosis (DVT).
• Angioplasty Patients Double Dosages And Reduce Heart Attack, Stroke And Death Clopidogrel anticlotting prescription, in doubled dosages minimizes risk of cardiovascular deaths, heart attaches ad strokes by 14%. Intensified bleeding in patients did rise by 40%, but proved to show zero percent increase in coronary artery bypass graft surgery patients, intracranial bleeding or fatalities.
• PLATO: Ticagrelor found superior to clopidogrel in CV death, MI and stroke, despite CYP2C19, ABCB1 genotypes This trial included patients (n=18,624) with acute coronary syndrome randomly assigned ticagrelor 180-mg loading dose and 90-mg twice-daily maintenance dose vs. clopidogrel 300- to 600-mg loading dose and 75-mg maintenance dose for 6 to 12 months.
• Ticagrelor, Prasugrel Overcome Platelet Reactivity Better than Clopidogrel Two studies presented August 29, 2010, at the European Society of Cardiology (ESC) Congress demonstrated the effectiveness of the newer P2Y12 inhibitor drugs ticagrelor and prasugrel in overcoming high platelet reactivity compared with the standard antiplatelet agent clopidogrel.

View all news